3//SEC Filing
Oncology Impact Fund (Cayman) Management L.P. 3
Accession 0001209191-19-008256
CIK 0001708493other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 6:45 PM ET
Size
14.8 KB
Accession
0001209191-19-008256
Insider Transaction Report
Form 3
Holdings
Series A Preferred Stock
Exercise: $0.00→ Common Stock (1,525,165 underlying)Series B Preferred Stock
Exercise: $0.00→ Common Stock (1,578,755 underlying)Series C Preferred Stock
Exercise: $0.00→ Common Stock (417,853 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2016-11-01Exp: 2026-11-01→ Common Stock (76,258 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2017-01-10Exp: 2027-01-10→ Common Stock (50,838 underlying)
UBS Oncology Impact Fund L.P.
10% Owner
Holdings
Series A Preferred Stock
Exercise: $0.00→ Common Stock (1,525,165 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2016-11-01Exp: 2026-11-01→ Common Stock (76,258 underlying)Series B Preferred Stock
Exercise: $0.00→ Common Stock (1,578,755 underlying)Series C Preferred Stock
Exercise: $0.00→ Common Stock (417,853 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2017-01-10Exp: 2027-01-10→ Common Stock (50,838 underlying)
Holdings
Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2017-01-10Exp: 2027-01-10→ Common Stock (50,838 underlying)Series A Preferred Stock
Exercise: $0.00→ Common Stock (1,525,165 underlying)Series B Preferred Stock
Exercise: $0.00→ Common Stock (1,578,755 underlying)Series C Preferred Stock
Exercise: $0.00→ Common Stock (417,853 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2016-11-01Exp: 2026-11-01→ Common Stock (76,258 underlying)
MPM BioImpact LLC
10% Owner
Holdings
Series A Preferred Stock
Exercise: $0.00→ Common Stock (1,525,165 underlying)Series B Preferred Stock
Exercise: $0.00→ Common Stock (1,578,755 underlying)Series C Preferred Stock
Exercise: $0.00→ Common Stock (417,853 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2016-11-01Exp: 2026-11-01→ Common Stock (76,258 underlying)Common Stock Warrant (Right to Buy)
Exercise: $0.05From: 2017-01-10Exp: 2027-01-10→ Common Stock (50,838 underlying)
Footnotes (3)
- [F1]All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- [F2]The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC.
- [F3]The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Documents
Issuer
Harpoon Therapeutics, Inc.
CIK 0001708493
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001721036
Filing Metadata
- Form type
- 3
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 6:45 PM ET
- Size
- 14.8 KB